�
SHR3680 � GT0918( Proxalutamide) � ONC1-13B
‣ Other early stage pipeline Antiandrogens and our view – � �
DR103
AZD3514 � HE3232( Apoptone) �
BMS-641988
‣ Androgen Synthesis inhibitors: TAK-700 and TOK-001 Failure in clinical trials creates“ No hope” for VT-464 & other Cyp17 lyase inhibitor?
� TAK-700- How it is different from Zytiga? � GALATERONE( TOK-001) � �
VT-464 ASN001
For More Info: https:// marketreportscenter. com / reports / 505877 / prostate-cancernewer-antiandrogens-emerging-therapies-targeting-a-watchfulwaiting-and-resistance-population
‣ Selective Androgen Receptor Degraders
� GTX-758
‣ Indirect near term key competitors to Zytiga / Xtandi in Post chemo setting: � � �
OGX-011 TAS-3681 ARV-330